PT2850082T - 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)ureia como inibidores de raf-cinase para o tratamento do cancro - Google Patents
1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)ureia como inibidores de raf-cinase para o tratamento do cancroInfo
- Publication number
- PT2850082T PT2850082T PT137120051T PT13712005T PT2850082T PT 2850082 T PT2850082 T PT 2850082T PT 137120051 T PT137120051 T PT 137120051T PT 13712005 T PT13712005 T PT 13712005T PT 2850082 T PT2850082 T PT 2850082T
- Authority
- PT
- Portugal
- Prior art keywords
- methyl
- pyrido
- dimethylbutyl
- pyrimidin
- methylamino
- Prior art date
Links
- HHCBMISMPSAZBF-UHFFFAOYSA-N LY3009120 Chemical compound CC1=NC2=NC(NC)=NC=C2C=C1C1=CC(NC(=O)NCCC(C)(C)C)=C(F)C=C1C HHCBMISMPSAZBF-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 title 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607702P | 2012-03-07 | 2012-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2850082T true PT2850082T (pt) | 2016-07-15 |
Family
ID=47884613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137120051T PT2850082T (pt) | 2012-03-07 | 2013-03-05 | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5-(7-metil-2-(metilamino)pirido[2,3-d]pirimidin-6-il)fenil)ureia como inibidores de raf-cinase para o tratamento do cancro |
Country Status (39)
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| BR112018075371A2 (pt) * | 2016-06-10 | 2019-03-19 | Novartis Ag | usos terapêuticos de um inibidor de c-raf |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| WO2018200981A1 (en) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Raf-degrading conjugate compounds |
| PL3728254T3 (pl) | 2017-12-21 | 2023-06-12 | Boehringer Ingelheim International Gmbh | Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1 |
| JP7161849B2 (ja) * | 2018-01-24 | 2022-10-27 | 株式会社クラレ | 第一級アミンの製造方法 |
| CN118903436A (zh) | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500389T1 (it) | 2018-12-28 | 2025-11-10 | Deciphera Pharmaceuticals Llc | Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti |
| JP7451543B2 (ja) | 2019-02-06 | 2024-03-18 | イーライ リリー アンド カンパニー | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
| TWI756636B (zh) * | 2019-02-18 | 2022-03-01 | 美商建南德克公司 | 嘧啶并嘧啶化合物及使用方法 |
| IL330104A (en) | 2019-03-11 | 2026-08-01 | Deciphera Pharmaceuticals Llc | Crystalline forms of rifatinib |
| CN114072148A (zh) * | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| HRP20231310T1 (hr) | 2019-05-10 | 2024-02-02 | Deciphera Pharmaceuticals, Llc | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene |
| HUE065486T2 (hu) | 2019-05-10 | 2024-05-28 | Deciphera Pharmaceuticals Llc | Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai |
| ES3072710T3 (en) | 2019-06-17 | 2026-07-03 | Deciphera Pharmaceuticals Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| HRP20260411T1 (hr) | 2019-08-12 | 2026-05-08 | Deciphera Pharmaceuticals, Llc | Ripretinib za liječenje gastrointestinalnih stromalnih tumora |
| US12691108B2 (en) | 2019-08-12 | 2026-07-28 | Deciphera Pharmaceuticals, Llc | Methods for treating vascular malformations |
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| CN116034106B (zh) | 2020-06-02 | 2025-11-04 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| JP7805363B2 (ja) | 2020-11-02 | 2026-01-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体 |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| TW202340208A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| TW202340209A (zh) | 2021-12-01 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441051A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes |
| CR20240233A (es) | 2021-12-01 | 2024-07-17 | Univ Vanderbilt | Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer |
| TW202337432A (zh) | 2021-12-01 | 2023-10-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 |
| EP4441050A1 (en) | 2021-12-01 | 2024-10-09 | Boehringer Ingelheim International GmbH | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| MX2024006627A (es) | 2021-12-03 | 2024-08-22 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos. |
| AU2022405115A1 (en) | 2021-12-09 | 2024-07-11 | Deciphera Pharmaceuticals, Llc | Raf kinase inhibitors and methods of use thereof |
| US12319655B2 (en) | 2021-12-09 | 2025-06-03 | Deciphera Pharmaceuticals, Llc | RAF kinase inhibitors and methods of use thereof |
| EP4452975A1 (en) | 2021-12-23 | 2024-10-30 | Boehringer Ingelheim International GmbH | 8-aza quinazolines as brain-penetrant sos1-inhibitors |
| WO2023173017A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors for treating disease |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| AU2023370123A1 (en) | 2022-10-26 | 2025-04-17 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| US20240174642A1 (en) | 2022-10-26 | 2024-05-30 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| WO2024088991A1 (en) | 2022-10-26 | 2024-05-02 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating sting |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| US20250019385A1 (en) | 2023-05-30 | 2025-01-16 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
| IL328681A (en) | 2023-12-08 | 2026-07-01 | Deciphera Pharmaceuticals Llc | Preparations containing vimseltinib |
| WO2025122942A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Solid state forms of a kinase inhibitor |
| AU2024404879A1 (en) | 2023-12-22 | 2026-06-25 | Regor Pharmaceuticals, Inc. | Sos1 inhibitors and uses thereof |
| WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202602876A (zh) | 2024-04-03 | 2026-01-16 | 德商百靈佳殷格翰國際股份有限公司 | 作為ｓｏｓ１抑制劑的新穎雙環芐基醯胺吡啶衍生物 |
| TW202608862A (zh) | 2024-05-01 | 2026-03-01 | 美商迪賽孚爾製藥有限公司 | 製備ｃｓｆ－１ｒ抑制劑之方法及其使用方法 |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026114918A1 (en) | 2024-11-27 | 2026-06-04 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer |
| US20260146050A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes |
| US20260146049A1 (en) | 2024-11-27 | 2026-05-28 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| WO2026114957A1 (en) | 2024-11-27 | 2026-06-04 | Boehringer Ingelheim International Gmbh | Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4383870B2 (ja) * | 2001-10-17 | 2009-12-16 | 協和発酵キリン株式会社 | 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| WO2004039782A1 (ja) * | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| UY33221A (es) * | 2010-02-09 | 2011-09-30 | Univ California | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
-
2013
- 2013-02-26 AR ARP130100576A patent/AR090151A1/es unknown
- 2013-02-27 TW TW102107122A patent/TW201348233A/zh unknown
- 2013-03-05 RS RS20160416A patent/RS54840B1/sr unknown
- 2013-03-05 ES ES13712005.1T patent/ES2584387T3/es active Active
- 2013-03-05 ME MEP-2016-124A patent/ME02423B/me unknown
- 2013-03-05 AU AU2013230146A patent/AU2013230146B2/en not_active Ceased
- 2013-03-05 US US14/383,799 patent/US9334267B2/en not_active Expired - Fee Related
- 2013-03-05 BR BR112014018528A patent/BR112014018528A8/pt not_active IP Right Cessation
- 2013-03-05 JP JP2014561029A patent/JP2015509536A/ja not_active Ceased
- 2013-03-05 CA CA2863673A patent/CA2863673A1/en not_active Abandoned
- 2013-03-05 HU HUE13712005A patent/HUE028095T2/en unknown
- 2013-03-05 EP EP13712005.1A patent/EP2850082B1/en active Active
- 2013-03-05 EA EA201491456A patent/EA024824B1/ru not_active IP Right Cessation
- 2013-03-05 PT PT137120051T patent/PT2850082T/pt unknown
- 2013-03-05 IN IN1575MUN2014 patent/IN2014MN01575A/en unknown
- 2013-03-05 MX MX2014010701A patent/MX2014010701A/es unknown
- 2013-03-05 WO PCT/US2013/029084 patent/WO2013134243A1/en not_active Ceased
- 2013-03-05 LT LTEP13712005.1T patent/LT2850082T/lt unknown
- 2013-03-05 HR HRP20160654TT patent/HRP20160654T1/hr unknown
- 2013-03-05 US US13/785,575 patent/US8741911B2/en not_active Expired - Fee Related
- 2013-03-05 WO PCT/US2013/029098 patent/WO2013134252A1/en not_active Ceased
- 2013-03-05 PE PE2014001381A patent/PE20142338A1/es not_active Application Discontinuation
- 2013-03-05 DK DK13712005.1T patent/DK2850082T3/en active
- 2013-03-05 NZ NZ627454A patent/NZ627454A/en not_active IP Right Cessation
- 2013-03-05 KR KR1020147024732A patent/KR20140129087A/ko not_active Abandoned
- 2013-03-05 HK HK15103082.6A patent/HK1202541A1/xx unknown
- 2013-03-05 SG SG11201404969YA patent/SG11201404969YA/en unknown
- 2013-03-05 CN CN201380012913.9A patent/CN104302646B/zh not_active Expired - Fee Related
- 2013-03-05 AP AP2014007899A patent/AP2014007899A0/xx unknown
- 2013-03-05 SI SI201330188A patent/SI2850082T1/sl unknown
- 2013-03-05 MA MA37316A patent/MA37316B1/fr unknown
- 2013-05-03 UA UAA201409109A patent/UA112340C2/uk unknown
-
2014
- 2014-07-24 CO CO14161404A patent/CO7010837A2/es unknown
- 2014-08-11 IL IL234052A patent/IL234052A/en not_active IP Right Cessation
- 2014-08-12 CR CR20140378A patent/CR20140378A/es unknown
- 2014-08-21 CL CL2014002220A patent/CL2014002220A1/es unknown
- 2014-09-03 TN TNP2014000375A patent/TN2014000375A1/fr unknown
- 2014-09-04 DO DO2014000200A patent/DOP2014000200A/es unknown
- 2014-09-05 EC ECIEPI201417584A patent/ECSP14017584A/es unknown
- 2014-09-05 PH PH12014501986A patent/PH12014501986A1/en unknown
-
2016
- 2016-07-22 CY CY20161100719T patent/CY1117846T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2850082T1 (sl) | 1-(3,3-dimetilbutil)-3-(2-fluoro-4-metil-5(7-metil-2-(metilamino) pirido(2,3-d)pirimidin-6-il)fenil)urea kot inhibitor Raf kinaze za zdravljenje raka | |
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| IL265918B (en) | Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors | |
| ZA201800771B (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| SI3418281T1 (sl) | Pirazolo(1,5-A)pirimidini, uporabni kot zaviralci kinaze ATR za zdravljenje rakavih obolenj | |
| SI2857404T1 (sl) | Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji | |
| IL245062B (en) | History of 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-h4-pyrido[3,2-b]pyrazine-8 -Il)oxy]phenyl]urea as raf inhibitors for cancer treatment | |
| SI3290421T1 (sl) | Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK) | |
| ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| SI2681219T1 (sl) | Derivati 6,7-dihidro-pirazolo(1,5-a)pirazin-4-ilamina uporabni kot inhibitorji beta-sekretaze (BACE) | |
| SI2935274T1 (sl) | 3-okso-2,3,5,8-tetrahidro-(1,2,4)triazolo(4,3-a)pirimidinski derivati za zdravljenje bolezni dihal | |
| IL234772A0 (en) | History of 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo, thiano or pyrrolo)[3,2-d]pyrimidin-4-one for cancer treatment | |
| GB201219129D0 (en) | Triazolo(4,5-d)pyrmindine compounds |